Rajagopal M, Thomas SV, Kathpalia PP, Chen Y, Pao AC. Prostaglandin E2 induces chloride secretion through crosstalk between cAMP and calcium signaling in mouse inner medullary collecting duct cells.
-Under conditions of high dietary salt intake, prostaglandin E2 (PGE2) production is increased in the collecting duct and promotes urinary sodium chloride (NaCl) excretion; however, the molecular mechanisms by which PGE2 increases NaCl excretion in this context have not been clearly defined. We used the mouse inner medullary collecting duct (mIMCD)-K2 cell line to characterize mechanisms underlying PGE2-regulated NaCl transport. When epithelial Na ϩ channels were inhibited, PGE2 exclusively stimulated basolateral EP4 receptors to increase short-circuit current (Isc PGE2 ). We found that Isc PGE2 was sensitive to inhibition by H-89 and CFTR-172, indicating that EP4 receptors signal through protein kinase A to induce Cl Ϫ secretion via cystic fibrosis transmembrane conductance regulator (CFTR). Unexpectedly, we also found that Isc PGE2 was sensitive to inhibition by BAPTA-AM (Ca 2ϩ chelator), 2-aminoethoxydiphenyl borate (2-APB) (inositol triphosphate receptor blocker), and flufenamic acid (FFA) [Ca 2ϩ -activated Cl Ϫ channel (CACC) inhibitor], suggesting that EP4 receptors also signal through Ca 2ϩ to induce Cl Ϫ secretion via CACC. Additionally, we observed that PGE2 stimulated an increase in Isc through crosstalk between cAMP and Ca 2ϩ signaling; BAPTA-AM or 2-APB inhibited a component of Isc PGE2 that was sensitive to CFTR-172 inhibition; H-89 inhibited a component of Isc PGE2 that was sensitive to FFA inhibition. Together, our findings indicate that PGE2 activates basolateral EP4 receptors and signals through both cAMP and Ca 2ϩ to stimulate Cl Ϫ secretion in IMCD-K2 cells. We propose that these signaling pathways, and the crosstalk between them, may provide a concerted mechanism for enhancing urinary NaCl excretion under conditions of high dietary NaCl intake. prostaglandin E2; EP4 receptor; collecting duct; cystic fibrosis transmembrane conductance regulator; Ca 2ϩ -activated Cl Ϫ channel THE COLLECTING DUCT OF THE KIDNEY maintains total body sodium chloride (NaCl) balance by fine-tuning urinary NaCl excretion in response to changes in dietary salt intake. Local changes in the hormonal milieu of the collecting duct play a critical role in this response mechanism. For example, high salt feeding of mice induces renal medullary production of prostaglandin E2 (PGE2) (12, 14, 23) , which could operate as a paracrine hormone to promote urinary NaCl excretion. Targeted deletion of microsomal prostaglandin E synthase (mPGES-1) in mice disrupts renal PGE2 production and induces salt-sensitive hypertension, indicating that PGE2 signaling contributes to NaCl balance and blood pressure regulation (13, 29) . The molecular mechanisms through which PGE2 increases urinary NaCl excretion, in the context of high dietary salt intake, have not been completely defined. PGE2 activates four subtypes of prostanoid receptors: EP1, EP2, EP3, and EP4 (9) . EP2 and EP4 receptors are classic G␣ s -coupled receptors, which increase intracellular cyclic AMP (cAMP) concentration, whereas EP1 receptors are G q -coupled receptors, which increase intracellular calcium (Ca 2ϩ ) concentration through an inositol triphosphate (IP 3 )-dependent pathway (9, 28) . EP3 receptors have multiple splice variants, which, depending on the interacting G protein, activate either G␣ s , G i , or G q proteins (9) .
PGE2 can stimulate various prostanoid receptors to increase Cl Ϫ secretion in the collecting duct (12, 16, 57, 68) . The physiological significance of Cl Ϫ secretion in the collecting duct may be most important under salt-loading conditions when extracellular fluid volume expansion leads to low levels of plasma aldosterone concentration and, as a consequence, diminished Na ϩ reabsorption through the epithelial sodium channel (ENaC) (32, 40, 41, 43, 56) . Under these circumstances, paracrine hormones, such as ATP, adenosine, and possibly PGE2, are synthesized and released by kidney epithelial cells and stimulate respective signaling pathways that promote Cl Ϫ secretion (12, 50, 60) . Notably, the initial segment of the inner medullary collecting duct (IMCD) is the only nephron segment that has been shown to secrete Cl Ϫ under salt-loading conditions (22, 62, 69) .
We used the mIMCD-K2 cell line as a model system to study the direct effects of PGE2 on NaCl transport across IMCD epithelia under conditions of diminished ENaC activity. The mIMCD-K2 cell line was derived from the initial segment of the IMCD and retains characteristic signaling and ion transport pathways of the IMCD (6, 7, 33, 66) . We demonstrate here that PGE2 activates basolateral EP4 receptors to increase Cl Ϫ secretion through cystic fibrosis transmembrane conductance regulator (CFTR). Although EP4 receptors are linked to G␣ s and cAMP signaling, we found that EP4 receptor activation also leads to stimulation of Cl Ϫ secretion through calcium-activated Cl Ϫ channels (CACC). Moreover, we found that PGE2-stimulated Cl Ϫ secretion involves crosstalk between cAMP and Ca 2ϩ -signaling pathways, in which CFTR-mediated short-circuit current (I sc ) is sensitive to inhibition by BAPTA-AM (Ca 2ϩ chelator) and 2-aminoethoxydiphenyl borate (2-APB) (IP 3 receptor blocker) and CACC-mediated I sc is sensitive to inhibition by H-89 [protein kinase A (PKA) inhibitor]. These findings indicate that PGE2 acts through a cAMP and Ca 2ϩ -signaling network to stimulate Cl Ϫ secretion in IMCD cells, which may serve as an adaptive response to enhance urinary NaCl excretion under conditions of high dietary NaCl intake.
MATERIALS AND METHODS
Cell culture. The mIMCD-K2 cell line was kindly provided by Dr. Bruce Stanton (Dartmouth Medical School, Hanover, NH). Cells of passages 38 -46 were expanded and plated on polycarbonate Snapwell inserts (surface area of 1.12 cm 2 , Corning Costar, Corning, NY), as described previously (55) . Transepithelial voltage (Vte) and resistance (Rte) were measured with an epithelial voltohmmeter "chopstick" voltmeter (World Precision Instruments, Sarasota, FL). Cells were grown in defined medium until R te reached values greater than 800 ⍀/cm 2 . Ussing chamber measurements. Cell sheets were mounted between the Lucite half chambers of the Ussing chamber apparatus (Physiologic Instruments, San Diego, CA) for electrophysiological studies, as described previously (52, 55) . Cell sheets were bathed in KrebsHenseleit solution (in mM: 140 NaCl, 25 NaHCO 3, 5 KCl, 5 glucose, 2 CaCl2, and 1 MgCl2) and gassed with a mixture of 95% O2 and 5% CO2. In ion-substitution experiments, Cl Ϫ in the Krebs-Henseleit was replaced with glutamate and sulfate, and HCO 3 Ϫ was replaced with HEPES to identify the ions responsible for PGE2-stimulated Isc (Isc  PGE2 ) . Vte across cell sheets was clamped to 0 mV, and a set voltage pulse of 1 mV was applied across cell sheets for 200 ms every 20 s. The Isc and Rte across cell sheets were continuously recorded using Acquire and Analyze Software (Physiologic Instruments). Electrophysiological responses were characterized in cells from at least three different passages to account for interpassage variability.
Pharmacological agents. Once Isc and Rte across cell sheets stabilized in the Ussing chamber, typically within 2-4 min of mounting, a series of pharmacological agents was added to cell sheets. In these experiments, no washout step was included in between addition of each agent. The apical side of all cell sheets was treated with the ENaC inhibitor amiloride (10 Ϫ5 M; Sigma, St. Louis, MO). PGE2 (7.7 ϫ 10 Ϫ8 M) was then added sequentially to the apical and basal sides of cell sheets or vice versa. In some experiments, the EP1/EP3 receptor agonist sulprostone (10 Ϫ6 M; Tocris Bioscience, Bristol, UK), the EP2 receptor agonist butaprost (10 Ϫ5 M, Sigma), or the EP4 agonist TCS2510 (10 Ϫ6 M, Tocris Bioscience) was added to the apical or basal side of cell sheets. In other experiments, the EP1/EP2 receptor antagonist AH-6809 (10 Ϫ6 M; Cayman Chemicals, Ann Arbor, MI), the EP1/EP3 receptor antagonist ONO-8713 (10 Ϫ6 M, Cayman Chemicals), or the EP4 receptor antagonist L-161,982 (10 Ϫ6 M, Tocris Bioscience) was added to cell sheets before PGE2 stimulation. Bromocresol green (3 ϫ 10 Ϫ5 M, Sigma) was used as a prostaglandin transport inhibitor to confirm transport of PGE2 across cell sheets.
To identify the classes of ion channels or transporters that respond to EP4 receptor activation, several small molecule inhibitors were Reverse transcriptase-PCR. mIMCD-K2 cells were grown to resistance on permeable supports, and total RNA was harvested using the RNeasy Mini Kit (Qiagen, Valencia, CA) according to manufacturer instructions. Total RNA from mouse kidney was obtained from Zyagen (San Diego, CA) to serve as positive control. Reverse tran- scriptase (RT) reactions were performed according to manufacturer instructions (New England BioLaboratories, Ipswich, MA). Thermal cycling parameters were the following: incubation at 98°C for 30 s followed by 35 cycles at 98°C for 10 s, 58°C for 10 s, 72°C for 50 s, and then a final extension at 72°C for 5 min. PCR primers were designed and used for detecting gene amplification of EP1, EP2, EP3, and EP4 receptors. The sequences were as follows: mouse EP1 Forward: 5=-AGCCTGCTTGCCATCGACCTA-3=, mouse EP1 Reverse: 5=-GCCAGGGTACTGTAACTCGTAGCGAC-3=; mouse EP2 Forward: 5=-AGGACTTCGATGGCAGAGGAGACGGACCACCT-CATTCTCC-3=, mouse EP2 Reverse: 5=-CAGCCCCTTACACTT-CTCCAATGAGGCCATTTAAAGACTT-3=; mouse EP3 Forward: 5=-CCAGCCACATGAAGACTCGCG-3=, mouse EP3 Reverse: 5=-TCATTATCAATAGCGGCGACCAA-3=; mouse EP4 Forward: 5=-CCATCGTAGTATTGTGCAAGTCGCG-3=, mouse EP4 Reverse: 5=-AAGGAGCTGAAGCCGGCGTAC-3=. Specificity of each set of primers was confirmed by BLAST search against GenBank and by direct sequencing of PCR products. PCR products were resolved using a 1% agarose gel dissolved Tris-Acetate EDTA buffer and visualized with ethidium bromide.
Statistics. Statistical analyses for comparisons between different treatment groups of mIMCD-K2 cells were performed using paired or unpaired two-tailed Student's t-tests. Differences were considered significant at P Ͻ 0.05.
RESULTS

PGE2 activates basolateral EP4 receptors to induce Cl
Ϫ secretion. Amiloride was first added to the apical side of mIMCD-K2 cells to study the effects of PGE2 on Cl Ϫ transport in the absence of ENaC activity. The addition of amiloride induced no significant changes to I sc ; we next added PGE2 (7.7 ϫ 10 Ϫ8 M PGE2) to either side of mIMCD-K2 cells and examined the I sc response. We chose a concentration of 7.7 ϫ 10 Ϫ8 M for PGE2 because this concentration has previously been used in IMCD cells to stimulate cAMP signaling (16, 38) . Addition of PGE2 to either side of cell sheets induced an initial transient followed by a sustained increase in I sc (Fig. 1A) .
We next generated a cumulative dose-response curve of the I sc response to basal addition of PGE2. We found that 10 Ϫ8 M was the smallest dose of PGE2 that increased I sc . Sequential addition of 10 Ϫ7 M and 10 Ϫ6 M of PGE2 progressively increased I sc ; addition of higher concentrations of PGE2, however, did not further increase I sc (Fig. 1B) . We measured the sustained increase in I sc PGE2 and plotted these values against the logarithm of PGE2 concentration (Fig. 1C) . The EC50 of the PGE2 I sc response was 3.1 Ϯ 0.2 ϫ 10 Ϫ8 M. We observed that PGE2 induced a different I sc response depending on which side PGE2 is added. Addition of PGE2 to the basal side elicited a maximal I sc PGE2 response, so addition of PGE2 to the apical side did not further stimulate I sc ( Fig. 2A , dashed line; Fig. 2B ). On the other hand, addition of PGE2 to the apical side elicited a partial I sc PGE2 response, which could be further enhanced with addition of PGE2 to the basal side ( Fig. 2A , solid line; Fig. 2C ). We also found that addition of PGE2 to either side of cells increased transepithelial conductance, a response that closely mirrored the increases in I sc (Fig.  2 , D and E). These findings suggest that a class of prostanoid receptors is preferentially localized to the basal side of mIMCD-K2 cells to initiate the I sc PGE2 response. To identify which class of prostanoid receptors is responsible for I sc
PGE2
, we stimulated mIMCD-K2 cells with a series of EP receptor agonists and examined the I sc response. Apical addition of the EP4 agonist TCS-2510 (10 Ϫ6 M) induced no change in I sc (Fig. 3, A and B) , whereas basal addition of TCS-2510 (10 Ϫ6 M) induced an increase in I sc (Fig. 3 , A and C), which closely mirrored and accounted for I sc
. Addition of EP1/EP3 receptor agonist sulprostone (10 Ϫ6 M) and the EP2 receptor agonist butaprost (10 Ϫ5 M) to either side of cell sheets induced no change in I sc (Fig. 3 , B and C).
As a complementary approach for identifying the EP receptors responsible for I sc PGE2 , we also pretreated mIMCD-K2 (Fig. 4) , as well as TCS-2510-stimulated I sc (data not shown), indicating that EP4 receptor activation is responsible for I sc PGE2 in mIMCD-K2 cells.
We observed that L-161,982 produced a different inhibitory response depending on which side L-161,982 was added. When L-161,982 (10 Ϫ7 M) was added to the apical bath before basal addition of PGE2, the I sc response was partly inhibited (Fig. 4C, solid line) ; in contrast, addition of L-161,982 to the basal bath before addition of PGE2 almost completely inhibited the I sc response (Fig. 4C, dashed line) . When L-161,982 was used at a lower concentration and added after PGE2 treatment, the sidedness of the inhibitory response became more apparent. Apical addition of L-161,982 (2.0 ϫ 10 Ϫ8 M) to PGE2-stimulated cells did not decrease I sc at 1 min ( . Moreover, the latency of I sc inhibition was different depending on which side L-161,982 was added. When L-161,982 was added to the apical side of cells, the lag time for inhibition of I sc PGE2 was 75 Ϯ 5 s, whereas it was 26.0 Ϯ 2.0 s when L-161,982 was added to the basal side. These findings again suggest that EP4 receptors are localized strictly to the basal membrane.
Although we observed a sidedness to the latency period for inhibition of I sc PGE2 by L-161,982, we observed no significant difference in sidedness to the latency period for PGE2-stimulated I sc . The lag time for I sc stimulation was 33 Ϯ 4 s and 28 Ϯ 2 s when PGE2 was added to the apical and basal side of cells, respectively. We hypothesized that addition of PGE2 to the apical side increases I sc because it is rapidly transported across mIMCD-K2 cell sheets to stimulate EP4 receptors present in the basolateral membrane. To test this, we incubated mIMCD-K2 cells with bromocresol green (3.0 ϫ 10 Ϫ5 M), an inhibitor of the prostaglandin transporter (5, 25, 31, 51) , and then added PGE2 to either side of cell sheets. We found that pretreatment of mIMCD-K2 cells with bromocresol green significantly inhibited I sc PGE2 when PGE2 was added to the apical [ din transporter transports PGE2 to the basolateral membrane; and 3) unlike PGE2, the EP4 receptor agonist TCS2510 does not appear to be a substrate for the prostaglandin transporter.
We next used RT-PCR to evaluate EP4 receptor mRNA expression in mIMCD-K2 cells. Mouse kidney cDNA were run in parallel as a positive control. We detected all four classes of EP receptors in mouse kidney homogenates. We also found that EP4 receptors, as well as EP1 and EP2 receptors, are expressed in mIMCD-K2 cells (Fig. 7) .
PGE2 stimulates Cl Ϫ secretion through CFTR and CACC. Because ENaC activity was blocked with addition of amiloride to the apical side of cell sheets in all experiments, we concluded that I sc PGE2 is likely caused by stimulation of electrogenic anion secretion. To verify that PGE2 stimulates Cl Ϫ secretion in mIMCD-K2 cells, we performed similar experiments in a Cl Ϫ -free, HEPES-buffered Krebs-Henseleit solution. As expected, addition of PGE2 to mIMCD-K2 cells in this bath solution induced no increase in I sc (Fig. 8) . We and others have identified CFTR and CACC as being candidate Cl Ϫ channels that mediate apical Cl Ϫ secretion in mIMCD-K2 cells (6, 53-55, 66, 67) . To identify the apical ion channels mediating Cl Ϫ secretion in the I sc PGE2 response, we treated PGE2-stimulated cells with CFTR inhibitor-172 (CFTR-172) and FFA. Apical addition of CFTR-172 (10 Ϫ5 M) attenuated I sc PGE2 by 60.1 Ϯ 2.7% (Fig. 9, A and B) ; surprisingly, apical addition of FFA (2 ϫ 10 Ϫ4 M), following CFTR-172 addition, also reduced I sc PGE2 by 25.7 Ϯ 1.7% (Fig. 9, A and B) . Addition of CFTR-172 and FFA also similarly inhibited transepithelial conductance (Fig. 9C) . Moreover, the inhibitory effects of CFTR-172 and FFA on I sc PGE2 were similar regardless of the order in which they were added to cell sheets (Fig.   9D) (Fig. 10) . To further characterize the transport pathway inhibited by DIDS, we next added acetazolamide (a carbonic anhydrase inhibitor) after bumetanide to PGE2-stimulated cells. In these experiments, basal addition of bumetanide decreased I sc PGE2 by 39.1 Ϯ 2.5% (Fig. 11 , A and C); basal addition of acetazolamide (2.0 ϫ 10 Ϫ4 M) further decreased I sc PGE2 by 32.4 Ϯ 3.6% (Fig. 11, B and C (Fig. 14, A and B) . Addition of FFA to cells had no effect on I sc PGE2 following BAPTA-AM treatment (Fig. 14D) .
Crosstalk exists between cAMP and Ca 2ϩ -signaling pathways. In the course of our experiments, we observed that a PKA-dependent pathway controls a component of I sc PGE2 that is sensitive to inhibition by FFA. In paired studies, addition of FFA to PGE2-stimulated cells led to a decrease in I sc of 1.8 Ϯ 0.2 A/cm 2 (Fig. 12C) (Fig. 15B) ; addition of FFA to 2-APB-treated cells induced no further inhibition of I sc PGE2 (Fig. 15, C and D) . Because the FFA-sensitive component of I sc PGE2 is completely blocked by 2-APB, we conclude that PGE2 signals through IP 3 receptors to activate CACC. Similar to the effect of BAPTA-AM on the CFTR-172-sensitive component of I sc PGE2 , addition of CFTR-172 to PGE2-stimulated cells, pretreated with 2-APB, led to a decrease in I sc of 1.05 Ϯ 0.14 A/cm 2 , which represented only 13.84 Ϯ 1.2% of I sc PGE2 (Fig. 15, C and D) . This finding also confirms that intracellular Ca 2ϩ is required for maximal PGE2-stimulated CFTR activity. We also observed that the magnitude of inhibition of I sc PGE2 after BAPTA-AM or 2-APB is much larger than the magnitude of inhibition of I sc PGE2 by FFA treatment. Addition of BAPTA-AM or 2-APB to PGE2-stimulated mIMCD-K2 cells inhibited I sc PGE2 by 60.6 Ϯ 5.6% (Fig. 14B ) or 78.5 Ϯ 4.5% (Fig. 15B) , respectively. In contrast, addition of FFA to paired PGE2-stimulated cells treated with vehicle decreased I sc PGE2 by only 34.0 Ϯ 2.9% (Figs. 14 and 15) . The discrepancy between the magnitude of inhibition of I sc PGE2 with BAPTA-AM or 2-APB with that after FFA treatment further suggests that BAPTA-AM or 2-APB may inhibit, not only CACC, but also CFTR activity in PGE2-stimulated mIMCD-K2 cells.
To evaluate whether direct stimulation of adenylate cyclase activity would also stimulate Ca 2ϩ signaling in mIMCD-K2 cells, we treated mIMCD-K2 cells with forskolin and examined the I sc response. Addition of forskolin (10 Ϫ5 M) to the apical side of cell sheets induced a large increase in I sc , which was inhibited by FFA (Fig. 16A, solid line; Fig. 16B ) or BAPTA-AM (Fig. 16A, dashed line; Fig. 16B ), indicating that an increase in cAMP signaling, independent of PGE2 action, can also stimulate CACC activity. Addition of BAPTA-AM to cells inhibited forskolin-stimulated I sc to a greater extent than the addition of FFA (Fig. 16B) , suggesting again that intracellular Ca 2ϩ stimulates, not only CACC, but also a component of CFTR activity.
To rule out the possibility that CFTR activity itself might regulate CACC, we incubated mIMCD-K2 cells with CFTR-172 before addition of PGE2. We found that PGE2 could still induce an increase in I sc , which was sensitive only to FFA inhibition (Fig. 17A, solid line) . When cells were incubated sequentially with CFTR-172, PGE2, and FFA, we observed no further inhibition of I sc with CFTR-172 treatment. Conversely, if cells were first incubated with FFA before addition of PGE2, PGE2 could still induce an increase in I sc (Fig. 17A, dashed line), which was almost completely inhibited by the subsequent addition of CFTR-172. These findings indicate that, although there is significant crosstalk between cAMP and Ca 2ϩ signaling in stimulating I sc PGE2 , CFTR-172-sensitive and FFA-sensitive Cl Ϫ channel activities are distinct and can be regulated independent of one another. To further test whether FFA and CFTR-172 inhibit distinct Cl Ϫ transport pathways, we used genistein, a tyrosine kinase inhibitor, to activate CFTR in a manner that is independent of Ca 2ϩ or cAMP-PKA signaling (1, 20, 26) . Addition of FFA induced no decrease in genistein-stimulated I sc , but addition of CFTR-172 completely inhibited genistein-stimulated I sc (Fig. 18) . This finding provides additional support that FFA and CFTR-172 can be used to probe distinct Cl Ϫ transport pathways in mIMCD-K2 cells.
DISCUSSION
In this study, we used the mIMCD-K2 cell line to examine direct effects of PGE2 on NaCl transport across IMCD epithelium. Our data demonstrate that PGE2 exclusively activates basolateral EP4 receptors to increase Cl Ϫ secretion (Fig. 18 ). The following findings support this conclusion. First, addition of PGE2 to the basal side of mIMCD-K2 cells elicited a maximal I sc PGE2 response; in contrast, addition of PGE2 to the apical side elicited a partial I sc PGE2 response, which could be further enhanced with basal addition of PGE2 (Fig. 2) . Second, basal, but not apical, addition of the EP4 receptor agonist TCS-2510 induced an increase in I sc , which closely mirrored the I sc PGE2 response (Fig. 3) . Third, addition of the EP4 receptor antagonist L-161,982 completely blocked I sc PGE2 (Fig.  4) , whereas addition of other classes of EP receptor antagonists had no effect on I sc
PGE2
. The magnitude and speed of this inhibition differed depending on whether L-161,982 was added to the apical or basal side of cells. Apical addition of L-161,982 led to partial inhibition of I sc PGE2 , whereas basal addition of L-161,982 led to complete and almost instantaneous inhibition of I sc PGE2 (Fig. 5) , suggesting that EP4 receptors are expressed on the basolateral side of mIMCD-K2 cells. Fourth, addition of a prostaglandin transporter inhibitor significantly inhibited I sc PGE2 but only when PGE2 was added to the apical side of mIMCD-K2 cells (Fig. 6) .
If our findings in mIMCD-K2 cells can be extrapolated to the in vivo setting, we suggest that PGE2 could arrive at the basolateral membrane of the IMCD from either the medullary interstitium or the collecting duct, which is known to synthesize and release PGE2 into the urinary space (8, 10, 27, 61) . Although it is apparent how PGE2 could directly access basolateral EP4 receptors from the medullary interstitium, PGE2 must take a more circuitous route to reach the basolateral membrane from the urinary space. The prostaglandin transporter (PGT) is expressed in the apical or subapical membrane of the collecting duct (2, 3, 30, 45) and mediates PGE2 uptake from the urinary space via an anion exchange mechanism, exchanging lactate for PGE2 (11) . In a Madin-Darby canine kidney cell model system, PGT extracts PGE2 from the apical solution and transports it across the epithelium to the basolateral solution (17) . Although the molecular details for how PGE2 traverses the kidney cell are not yet clear, PGE2 may reach the exterior of the basolateral membrane through the organic anion transporter 3, which is expressed on the basolateral surface of renal tubules (44, 58) . We infer from these and our own experiments that PGT carries PGE2 from the apical to basal side of IMCD cells, where it activates EP4 receptors in an autocrine or paracrine fashion (Fig. 18) . It is noteworthy that high dietary salt intake induces transcription of PGT gene in the mouse renal collecting duct, which may represent an adaptive mechanism for increasing delivery of PGE2 to the basolateral membrane of IMCD cells to stimulate EP4 receptors (14) .
Studies with EP4 receptor knockout mice and EP4 receptorselective agonists/antagonists have demonstrated that EP4 receptors play a critical role in numerous physiological functions, including promoting urinary salt and water excretion. EP4 receptors are expressed in rat IMCD cells (65) and isolated mouse IMCD tubules (35) . Moreover, addition of EP4 receptor agonists increase intracellular cAMP concentration in freshly isolated IMCD tubules, indicating that EP4 receptor signaling is intact in isolated IMCD tubules (35) . In a hyperprostaglandin E/antenatal Bartter syndrome model in which mice are treated chronically with furosemide, genetic deletion or pharmacological inhibition of EP4 receptors results in a blunted diuretic and natriuretic response, which is associated with an attenuation of the expected rise in plasma renin concentration. The blunted diuretic/natriuretic response in EP4 knockout mice is not accompanied by a change in glomerular filtration (46); these findings are consistent with the notion that PGE2 stimulates EP4 receptors in IMCD cells to increase tubular NaCl secretion.
In a similar study examining PGE2 effects on Cl Ϫ secretion, Sandrasagra and colleagues (57) found that, in the presence of amiloride, addition of PGE2 to either side of M1 cortical collecting duct cells stimulates diphenylamine-2-carboxylic acid-sensitive Cl Ϫ secretion. In our study with mIMCD-K2 cells, we conclude that PGE2, by activating basolateral EP4 receptors, increases Cl Ϫ secretion by stimulating basolateral Cl Ϫ entry through Cl Ϫ /HCO 3 Ϫ exchange and NKCC transport and apical Cl Ϫ exit through CACC and CFTR. Moreover, our experiments demonstrate that PGE2 stimulates Cl Ϫ secretion through crosstalk between cAMP and Ca 2ϩ signaling pathways in which cAMP and intracellular Ca 2ϩ also regulate CACC and CFTR activities, respectively (Fig. 18) . To our knowledge, this is the first demonstration of crosstalk between these two signaling pathways in kidney epithelial cells.
Several lines of evidence support the existence of crosstalk between cAMP and Ca 2ϩ -signaling pathways. First, FFA did not inhibit I sc PGE2 to the same extent as BAPTA-AM or 2-APB: the magnitude of inhibition of I sc PGE2 after BAPTA-AM or 2-APB was much larger than the magnitude of inhibi- tion of I sc PGE2 after FFA treatment (Figs. 14 and 15 ). This discrepancy suggests that BAPTA-AM or 2-APB may inhibit, not only CACC, but also CFTR activity in PGE2-stimulated mIMCD-K2 cells. Second, maneuvers that decrease intracellular Ca 2ϩ concentration (BAPTA-AM or 2-APB treatment) significantly decreased CFTR-172-sensitive I sc PGE2 in mIMCD-K2 cells (Figs. 14 and 15 ). Because CFTR is classically linked to PKA signaling, the sensitivity of CFTR activity to chelation of intracellular Ca 2ϩ suggests that a component of CFTR activity responds to Ca 2ϩ signaling. This finding adds to growing evidence in other epithelia that Ca 2ϩ -mobilizing secretagogues can activate CFTR (4, 15, 42, 64) . Third, the PKA inhibitor H-89 significantly blocked FFA-sensitive I sc PGE2 (Fig. 12) . The sensitivity of CACC activity to H-89 inhibition suggests that PKA, in addition to regulating CFTR, may also regulate CACC activity. Fourth, PGE2 could stimulate FFA-sensitive I sc PGE2 , even after maximal CFTR-172 inhibition (Fig. 17) . Additionally, CFTR-172, but not FFA, decreased genistein-stimulated I sc . Genistein activates CFTR independent of Ca 2ϩ or cAMP/PKA signaling; the last two findings indicate that FFA and CFTR-172 can be used to probe distinct Cl Ϫ transport pathways and that activity of CFTR or CACC does not directly regulate the activity of the other channel in mIMCD-K2 cells.
We used a wide array of small molecule inhibitors to characterize the activities of ion transporters and channels and their signaling intermediates in the I sc PGE2 response. Our findings should be interpreted with some caution because small molecule inhibitors may not always specifically inhibit their intended targets. For example, we tried to confirm the inhibitory effects of H-89 with myristolated PKA inhibitor (mPKI), a more specific inhibitor of PKA, but we were unable to recapitulate the inhibitory effects of H-89 on I sc PGE2 with low doses of mPKI (data not shown). In another example, the inhibitory effects of BAPTA-AM on I sc PGE2 occurred over a period of 20 min, which we suggest is consistent with Ca 2ϩ chelation and gradual inhibition of CACC activity, but we cannot rule out the possibility that BAPTA-AM inhibits other pathways regulating CACC activity. In a third example, FFA may inhibit other Cl Ϫ transport pathways in mIMCD-K2 cells. During the preparation of this manuscript, small molecule compounds that are potentially more specific for CACC became available through Tocris Bioscience. These new inhibitors may prove useful in characterizing I sc PGE2 and confirming CACC activity in mIMCD-K2 cells. To address some of these limitations, we used agonists or antagonists targeting different components of signaling and transport pathways, and the aggregate findings provide a coherent set of mechanisms for the I sc PGE2 response in mIMCD-K2 cells. Future studies using new biochemical and genetic approaches to modulate these signaling and transport pathways will ultimately be required to provide a more complete understanding of mechanisms underlying PGE2 action in these cells.
The role of cAMP/PKA signaling in regulating CACC is currently not clear. Several studies have shown that inhibiting components of the cAMP/PKA signaling pathway, including CFTR itself, can decrease CACC-mediated Cl Ϫ transport (47) (48) (49) 70) . We observed that inhibition of PKA significantly decreased, not only the CFTR-172-sensitive component of I sc PGE2 , but also the FFA-sensitive component, suggesting that PKA activation potentiates Ca 2ϩ -activated Cl Ϫ secretion in mIMCD-K2 cells. In contrast, we observed no change in the FFA-sensitive component of I sc PGE2 when mIMCD-K2 cells were pretreated with CFTR inhibitor-172, indicating that CFTR does not simply regulate the activity of CACC. The mechanisms by which cAMP/PKA signaling potentiates CACC remain to be characterized, but we suggest one mechanism in which PGE2 induces PKA-mediated phosphorylation of IP 3 receptors, which may sensitize them to basal levels of IP 3 (24, 63) . This could lead to an augmented IP 3 receptor response and provide a mechanism through which PGE2 activates PKA and subsequently contributes to Ca 2ϩ signaling (Fig. 18) . (53) and may also drive Ca 2ϩ -activated Cl Ϫ secretion. Our findings suggest a molecular mechanism through which PGE2 enhances urinary NaCl excretion under high-salt conditions. High-salt feeding increases expression of enzymes that increase PGE2 production, including cyclooxygenase (COX)-1, COX-2, and mPGES1, in the renal medulla (27, 29, 59) . As a consequence, high-salt feeding increases the PGE2 concentration in the renal medulla and urine (12, 21, 36, 37, 72) . When PGE2 production is disrupted through deletion of COX-1 or mPGES-1 in mice, salt-sensitive hypertension ensues (29, 72) .
We propose that PGE2 activates basolateral EP4 receptors in IMCD cells to stimulate Cl Ϫ secretion as an adaptive mechanism in which local increases in PGE2 production in the collecting duct serve to enhance urinary NaCl excretion under conditions of high dietary NaCl intake. The activation of these signaling pathways may be particularly important under states of extracellular fluid volume expansion, when levels of serum aldosterone are low and ENaC activity is suppressed. To date, the contribution of EP4 receptors to the control of NaCl balance and blood pressure in vivo is unclear and awaits activates Ca 2ϩ -activated Cl Ϫ channel (CACC) and perhaps CFTR activity.
